Roche says its new biomarker program benefits from the firm's unique diagnostics expertise. But like all its competitors embarked on similar efforts, Roche won't know the value of this complex underta
The best-performing business at troubled Roche is its diagnostics unit—the number one player in its industry. But can it stay on top in a new era of diagnostics? By Wendy Diller When Roche bought C